Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

  • Martínez Martín, Sandra
  • Alonso-Casal, Guzman
  • Arqués, Oriol
  • GARRALDA, Elena
  • Beaulieu, Marie-Eve
  • Casacuberta-Serra, Sílvia
  • Foradada Felip, Laia
  • Perez-Lopez, Raquel
  • Whitfield, Jonathan
  • Soucek, Laura
  • Moreno, Victor
MYC; Solid tumors, MYC; Tumores sólidos, MYC; Tumors sòlids, Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and tolerability as primary outcomes and pharmacokinetics, recommended phase 2 dose and preliminary signs of activity as secondary ones. A classical 3 + 3 design was used for dose escalation of weekly intravenous, single-agent OMO-103 administration in 21-day cycles, encompassing six dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions, occurring in ten patients. One dose-limiting toxicity occurred at DL5. Pharmacokinetics showed nonlinearity, with tissue saturation signs at DL5 and a terminal half-life in serum of 40 h. Of the 19 patients evaluable for response, 12 reached the predefined 9-week time point for assessment of drug antitumor activity, eight of those showing stable disease by computed tomography. One patient defined as stable disease by response evaluation criteria in solid tumors showed a 49% reduction in total tumor volume at best response. Transcriptomic analysis supported target engagement in tumor biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended phase 2 dose was determined as DL5 (6.48 mg kg−1). ClinicalTrials.gov identifier: NCT04808362., The authors from Vall d’Hebron Institute of Oncology (VHIO) thank the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support on this research. They also acknowledge the State Agency for Research (Agencia Estatal de Investigación) for financial support as Center of Excellence Severo Ochoa (no. CEX2020-001024-S/AEI/10.13039/501100011033). We thank the teams at Abzu and Biognosys for their valuable service and feedback, and M.-A. Morcillo for his help in the interpretation of PK data. This research has received funding from the Generalitat de Catalunya (AGAUR grant no. 2021/SGR 01509); from the European Union Horizon 2020 research and innovation program under grant agreement nos. 872212 and 101144681; from the Ministerio de Ciencia e Innovación, grant no. RTC2019-007067; from the Ministerio de Ciencia, Innovación y Universidades, grant nos. CPP2022-009808 and PLEC2021-007959 by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

  • Martínez Martín, Sandra
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel
  • López-Estévez, Sergio
  • Thabussot, Hugo
  • Beaulieu, Marie-Eve
  • Soucek, Laura
  • Foradada Felip, Laia
  • Kaur, Jastrinjan
  • Serrano del Pozo, Erika
Omomyc; Mass spectrometry; Protein therapeutics, Omomyc; Espectrometría de masas; Terapéutica de proteínas, Omomyc; Espectrometria de masses; Terapèutica de proteïnes, MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 872212 and from the Ministerio de Ciencia e Innovacion under grant no. RTC2019-007067-1.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

  • Castillo, Francisco
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Myc; descobriment de fàrmacs; Interaccions proteïna-ADN, Myc; Descubrimiento de fármacos; Interacciones proteína-ADN, Myc; Drug discovery; Protein–DNA interactions, Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. Indubitably though, its crucial and non-redundant role in cancer biology makes it an attractive target. However, achieving successful clinical Myc inhibition has proven challenging so far, as this nuclear protein is an intrinsically disordered polypeptide devoid of any classical ligand binding pockets. Indeed, Myc only adopts a (partially) folded structure in some contexts and upon interacting with some protein partners, for instance when dimerizing with MAX to bind DNA. Here, we review the cumulative knowledge on Myc structure and biophysics and discuss the implications for its biological function and the development of improved Myc inhibitors. We focus this biophysical walkthrough mainly on the basic region helix–loop–helix leucine zipper motif (bHLHLZ), as it has been the principal target for inhibitory approaches so far., This research was funded by the European Commission (SME Instrument, Grant no. 872212) and European Research Council (CoG grant no. 617473).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

  • Massó Vallés, Daniel
  • Soucek, Laura
Inhibició de Myc; Càncer; Omomyc, Inhibición de myc; Cáncer; Omomyc, Myc inhibition; Cancer; Omomyc, First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein—following the surprising discovery of its cell-penetrating capacity—constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic., This research was funded by the European Commission (SME Instrument, Grant no. 872212), the Instituto de Salud Carlos III (FIS grant no. PI16-01224) and the European Research Council (CoG grant no. 617473).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blocking Myc to treat cancer, reflecting on two decades of Omomyc

  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Soucek, Laura|||0000-0002-4750-7971
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural and biophysical insights into the function of the intrinsically disordered Myc oncoprotein

  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Castillo, Francisco
  • Soucek, Laura|||0000-0002-4750-7971
Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. Indubitably though, its crucial and non-redundant role in cancer biology makes it an attractive target. However, achieving successful clinical Myc inhibition has proven challenging so far, as this nuclear protein is an intrinsically disordered polypeptide devoid of any classical ligand binding pockets. Indeed, Myc only adopts a (partially) folded structure in some contexts and upon interacting with some protein partners, for instance when dimerizing with MAX to bind DNA. Here, we review the cumulative knowledge on Myc structure and biophysics and discuss the implications for its biological function and the development of improved Myc inhibitors. We focus this biophysical walkthrough mainly on the basic region helix-loop-helix leucine zipper motif (bHLHLZ), as it has been the principal target for inhibitory approaches so far.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue

  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Serrano del Pozo, Erika|||0000-0003-2417-1499
  • Thabussot, Hugo
  • Soucek, Laura|||0000-0002-4750-7971
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

  • Castillo, Francisco
  • Beaulieu, Marie-Eve
  • Soucek, Laura
Myc; descobriment de fàrmacs; Interaccions proteïna-ADN, Myc; Descubrimiento de fármacos; Interacciones proteína-ADN, Myc; Drug discovery; Protein–DNA interactions, Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. Indubitably though, its crucial and non-redundant role in cancer biology makes it an attractive target. However, achieving successful clinical Myc inhibition has proven challenging so far, as this nuclear protein is an intrinsically disordered polypeptide devoid of any classical ligand binding pockets. Indeed, Myc only adopts a (partially) folded structure in some contexts and upon interacting with some protein partners, for instance when dimerizing with MAX to bind DNA. Here, we review the cumulative knowledge on Myc structure and biophysics and discuss the implications for its biological function and the development of improved Myc inhibitors. We focus this biophysical walkthrough mainly on the basic region helix–loop–helix leucine zipper motif (bHLHLZ), as it has been the principal target for inhibitory approaches so far., This research was funded by the European Commission (SME Instrument, Grant no. 872212) and European Research Council (CoG grant no. 617473).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

  • Martínez Martín, Sandra
  • Alonso-Casal, Guzman
  • Arqués, Oriol
  • GARRALDA, Elena
  • Beaulieu, Marie-Eve
  • Casacuberta-Serra, Sílvia
  • Foradada Felip, Laia
  • Perez-Lopez, Raquel
  • Whitfield, Jonathan
  • Soucek, Laura
  • Moreno, Victor
MYC; Solid tumors, MYC; Tumores sólidos, MYC; Tumors sòlids, Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and tolerability as primary outcomes and pharmacokinetics, recommended phase 2 dose and preliminary signs of activity as secondary ones. A classical 3 + 3 design was used for dose escalation of weekly intravenous, single-agent OMO-103 administration in 21-day cycles, encompassing six dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions, occurring in ten patients. One dose-limiting toxicity occurred at DL5. Pharmacokinetics showed nonlinearity, with tissue saturation signs at DL5 and a terminal half-life in serum of 40 h. Of the 19 patients evaluable for response, 12 reached the predefined 9-week time point for assessment of drug antitumor activity, eight of those showing stable disease by computed tomography. One patient defined as stable disease by response evaluation criteria in solid tumors showed a 49% reduction in total tumor volume at best response. Transcriptomic analysis supported target engagement in tumor biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended phase 2 dose was determined as DL5 (6.48 mg kg−1). ClinicalTrials.gov identifier: NCT04808362., The authors from Vall d’Hebron Institute of Oncology (VHIO) thank the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support on this research. They also acknowledge the State Agency for Research (Agencia Estatal de Investigación) for financial support as Center of Excellence Severo Ochoa (no. CEX2020-001024-S/AEI/10.13039/501100011033). We thank the teams at Abzu and Biognosys for their valuable service and feedback, and M.-A. Morcillo for his help in the interpretation of PK data. This research has received funding from the Generalitat de Catalunya (AGAUR grant no. 2021/SGR 01509); from the European Union Horizon 2020 research and innovation program under grant agreement nos. 872212 and 101144681; from the Ministerio de Ciencia e Innovación, grant no. RTC2019-007067; from the Ministerio de Ciencia, Innovación y Universidades, grant nos. CPP2022-009808 and PLEC2021-007959 by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

  • Massó Vallés, Daniel
  • Soucek, Laura
Inhibició de Myc; Càncer; Omomyc, Inhibición de myc; Cáncer; Omomyc, Myc inhibition; Cancer; Omomyc, First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein—following the surprising discovery of its cell-penetrating capacity—constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic., This research was funded by the European Commission (SME Instrument, Grant no. 872212), the Instituto de Salud Carlos III (FIS grant no. PI16-01224) and the European Research Council (CoG grant no. 617473).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

  • Martínez Martín, Sandra
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel
  • López-Estévez, Sergio
  • Thabussot, Hugo
  • Beaulieu, Marie-Eve
  • Soucek, Laura
  • Foradada Felip, Laia
  • Kaur, Jastrinjan
  • Serrano del Pozo, Erika
Omomyc; Mass spectrometry; Protein therapeutics, Omomyc; Espectrometría de masas; Terapéutica de proteínas, Omomyc; Espectrometria de masses; Terapèutica de proteïnes, MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 872212 and from the Ministerio de Ciencia e Innovacion under grant no. RTC2019-007067-1.